关键词: 矮小, 生长激素, 类胰岛素生长因子-1, 芳香化酶抑制剂, 软骨发育不全

Abstract: Children’s height has been more and more concerned about by the society，parents and pediatricians. We discussed the research progress of drugs to improve growth of pediatric patients with short stature. Growth and final height are related to heredity，intrauterine development，postnatal nutrition，environment and endocrine hormones. New data confirm the known-efficacy of recombinant human growth hormone（rhGH） in growth hormone deficiency（GHD） and idiopathic short stature，and long-acting recombinant human growth hormone（LA-rhGH） in GHD. In future，the research and development of LA-rhGH and its clinical trials to expand the indications will be mainly carried out. Recombinant human insulin growth factor-1（rhIGF-1） is the main drug in the treatment of IGF-1 deficiency，and hypoglycemia and neoplasm should be monitored. GnRHa and the third generation of nonsteroidal aromatase inhibitors（AIs）can effectively delay epiphyseal fusion，and when combined with rhGH treatment it is beneficial to improve height. However，its efficacy is related to the etiology，age，heredity，treatment course and other factors. Long-term safety，efficacy and economy of the GnRHa or AIs should be considered comprehensively to make careful evaluation and selection. The modified recombinant C-type natriuretic peptide has completed the phase Ⅲ clinical trial, which has certain benefits to improve the height of children with achondroplasia. Some safe，effective，high-quality and stable new drugs were expected to be developed in order to enhance growth and promote their physical and mental health.

Key words: short stature, growth hormone, IGF-1, aromatase inhibitors, achondroplasia